Namodenoson
Namodenoson (pronunciation: na-mo-de-no-son) is a novel drug currently under investigation for its potential therapeutic applications in the treatment of liver diseases and cancer.
Etymology
The term "Namodenoson" is derived from the combination of the words "adenosine" and "modulator". The prefix "Namo" is a common prefix in pharmaceutical nomenclature, often used to denote a novel or modified version of a drug.
Pharmacology
Namodenoson is a selective A3 adenosine receptor (A3AR) agonist. A3AR is over-expressed in pathological cells, such as cancer or inflamed cells, but not in normal cells. This makes Namodenoson a potential therapeutic agent for diseases where A3AR is over-expressed.
Clinical Trials
Namodenoson has been studied in several clinical trials for its potential use in the treatment of non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). The drug has shown promising results in pre-clinical and early clinical trials, but further research is needed to confirm its efficacy and safety.
Related Terms
See Also
External links
- Medical encyclopedia article on Namodenoson
- Wikipedia's article - Namodenoson
This MedicineGPT article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski